Statins (inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase), the first-line treatment for dyslipidemia, decrease the levels of LDL cholesterol and significantly reduce the risk of the development and progression of atherosclerosis, cardiovascular morbidity, and mortality, as well as the need for re-vascularization [14]. This evidence concerns the gene HMGCR and atherosclerosis.